farmaecFARMAKOEKONOMIKA. Modern Pharmacoeconomics and PharmacoepidemiologyФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология2070-49092070-4933IRBIS LLC10.17749/2070-4909/farmakoekonomika.2026.325farmaec-1384Research ArticleREVIEW ARTICLESОБЗОРНЫЕ ПУБЛИКАЦИИConcepts aimed at improving pharmaceutical care for patients with socially significant diseases in Russia and worldwideКонцепции совершенствования лекарственной помощи пациентам с социально значимыми заболеваниями в России и миреhttps://orcid.org/0000-0003-1377-4796ГущинаЮ. Ш.GushchinaYu. Sh.

Гущина Юлия Шамилевна, доцент

ул. Миклухо-Маклая, д. 6, Москва 117198

Yulia Sh. Gushchina, Assoc. Prof.

6 Miklukho-Maklay Str., Moscow 117198

gushchina-yush@rudn.ruhttps://orcid.org/0000-0001-7178-1260АбрамовА. Ю.AbramovA. Yu.

Абрамов Алексей Юрьевич, д.м.н., проф.

ул. Миклухо-Маклая, д. 6, Москва 117198

Aleksey Yu. Abramov, Dr. Sci. Med., Prof.

6 Miklukho-Maklay Str., Moscow 117198

Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов им. Патриса Лумумбы»РоссияPeoples' Friendship University of Russia named after Patrice LumumbaRussian Federation202607052026119200210Copyright © Gushchina Y.S., Abramov A.Y., 20262026Гущина Ю.Ш., Абрамов А.Ю.Gushchina Y.S., Abramov A.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacoeconomics.ru/jour/article/view/1384

Objective: To conduct a comparative analysis of concepts aimed at improving pharmaceutical care for patients with socially significant diseases in both Russia and other countries with the purpose of identifying priority development directions for the Russian system.Material and methods. A systematic search of scientific literature, regulatory documents, and statistical data for 2016–2025 was conducted using the PubMed/MEDLINE, CyberLeninka, and eLibrary databases. A comparative method was applied to analyze European, North American, and Russian pharmaceutical provision models. Their effectiveness was evaluated based on accessibility, financial sustainability, quality of care, and innovation criteria.Results. The European model is characterized by a high level of government funding (70–80%) and effective cost control mechanisms through health technology assessment institutions. The North American system demonstrates trends toward universal coverage with multiple funding sources. The Russian model provides 100% coverage for high-cost nosologies, however, the overall share of government funding reaches 40% with a significant regional differentiation in accessibility. Current trends include implementation of personalized medicine, targeted therapy, telemedicine, and risk-sharing agreements with pharmaceutical companies.Conclusion. Priority directions for improving the Russian system include unification of regional approaches, implementation of clinical and economic effectiveness assessment mechanisms, development of personalized medicine and digital technologies for pharmaceutical care management.

Цель: провести сравнительный анализ концепций совершенствования лекарственной помощи пациентам с социально значимыми заболеваниями в России и зарубежных странах для определения приоритетных направлений развития отечественной системы.Материал и методы. Осуществлен систематический поиск научной литературы, нормативно-правовых документов и статистических данных за период 2016–2025 гг. в базах данных PubMed/MEDLINE, КиберЛенинка и eLibrary. Применялся сравнительно-аналитический метод для сопоставления европейской, североамериканской и российской моделей лекарственного обеспечения. Оценка эффективности проводилась по критериям доступности, финансовой устойчивости, качества помощи и инновационности.Результаты. Европейская модель характеризуется высокой степенью государственного финансирования (70–80%) и эффективными механизмами контроля затрат через институты оценки медицинских технологий. Североамериканская система демонстрирует тенденции к универсализации покрытия при множественных источниках финансирования. Российская модель обеспечивает 100% покрытие высокозатратных нозологий, однако общая доля государственного финансирования составляет 40% при значительной региональной дифференциации доступности. Современные тенденции включают внедрение персонализированной медицины, таргетной терапии, телемедицины и соглашений о разделении рисков с фармацевтическими компаниями.Заключение. Приоритетными направлениями совершенствования российской системы являются унификация региональных подходов, внедрение механизмов оценки клинико-экономической эффективности, развитие персонализированной медицины и цифровых технологий управления лекарственной помощью.

социально значимые заболеваниялекарственная помощьвысокозатратные нозологииперсонализированная медицинацифровые технологииsocially significant diseasespharmaceutical carehigh-cost nosologiespersonalized medicinedigital technologiesReferencesВоропинова О.А., Киселева И.Н., Нестеренко А.В. Социально значимые заболевания: динамические характеристики, факторы роста, проблемы учета и управления. Экономика: вчера, сегодня, завтра. 2023; 13 (11-1): 357–70.Воропинова О.А., Киселева И.Н., Нестеренко А.В. Социально значимые заболевания: динамические характеристики, факторы роста, проблемы учета и управления. Economics: Yesterday, Today and Tomorrow. 2023; 13 (11-1): 357–70 (in Russ.).Гринин Л.Е., Гринин А.Л., Коротаев А.В. Глобальное старение как интегральная проблема будущего. Социологический журнал. 2023; 29 (2): 110–31. https://doi.org/10.19181/socjour.2023.29.2.6.Grinin L.E., Grinin A.L., Korotayev A.V. Aging of the global population as an integral problem of the future. Sociological Journal. 2023; 29 (2): 110–31 (in Russ.). https://doi.org/10.19181/socjour.2023.29.2.6.Henman M.C., Ravera S., Lery F.X. Council of Europe Resolution on the Implementation of Pharmaceutical Care – a step forward in enhancing the appropriate use of medicines and patient-centred care. Healthcare. 2024; 12 (2): 232. https://doi.org/10.3390/healthcare12020232.Henman M.C., Ravera S., Lery F.X. Council of Europe Resolution on the Implementation of Pharmaceutical Care – a step forward in enhancing the appropriate use of medicines and patient-centred care. Healthcare. 2024; 12 (2): 232. https://doi.org/10.3390/healthcare12020232.Flessa S., Huebner C. Innovations in health care – a conceptual framework. Int J Environ Res Public Health. 2021; 18 (19): 10026. https://doi.org/10.3390/ijerph181910026.Flessa S., Huebner C. Innovations in health care – a conceptual framework. Int J Environ Res Public Health. 2021; 18 (19): 10026. https://doi.org/10.3390/ijerph181910026.Orhan R., Paric M., Czabanowska K. Lessons learnt from the EU response to NCDs: a content analysis on building resilient post-COVID health systems. Healthcare. 2021; 9 (12): 1659. https://doi.org/10.3390/healthcare9121659.Orhan R., Paric M., Czabanowska K. Lessons learnt from the EU response to NCDs: a content analysis on building resilient post-COVID health systems. Healthcare. 2021; 9 (12): 1659. https://doi.org/10.3390/healthcare9121659.Vallano A., Pontes C., Agustí A. The challenges of access to innovative medicines with limited evidence in the European Union. Front Pharmacol. 2023; 14: 1215431. https://doi.org/10.3389/fphar.2023.1215431.Vallano A., Pontes C., Agustí A. The challenges of access to innovative medicines with limited evidence in the European Union. Front Pharmacol. 2023; 14: 1215431. https://doi.org/10.3389/fphar.2023.1215431.European Parliamentary Research Service. Improving access to medicines and promoting pharmaceutical information. Available at: https://www.europarl.europa.eu/RegData/etudes/STUD/2023/753166/EPRS_STU(2023)753166_EN.pdf (accessed 10/06/2025).European Parliamentary Research Service. Improving access to medicines and promoting pharmaceutical information. Available at: https://www.europarl.europa.eu/RegData/etudes/STUD/2023/753166/EPRS_STU(2023)753166_EN.pdf (accessed 10/06/2025).Canfell O.J., Davidson K., Woods L., et al. Precision public health for non-communicable diseases: an emerging strategic roadmap and multinational use cases. Front Public Health. 2022; 10: 854525. https://doi.org/10.3389/fpubh.2022.854525.Canfell O.J., Davidson K., Woods L., et al. Precision public health for non-communicable diseases: an emerging strategic roadmap and multinational use cases. Front Public Health. 2022; 10: 854525. https://doi.org/10.3389/fpubh.2022.854525.Budreviciute A., Damiati S., Sabir D.K., et al. Management and prevention strategies for non-communicable diseases (NCDs) and their risk factors. Front Public Health. 2020; 8: 574111. https://doi.org/10.3389/fpubh.2020.574111.Budreviciute A., Damiati S., Sabir D.K., et al. Management and prevention strategies for non-communicable diseases (NCDs) and their risk factors. Front Public Health. 2020; 8: 574111. https://doi.org/10.3389/fpubh.2020.574111.Santiago A. Healthy China 2030: a plan towards growth, development and innovation in health sector. 2021. Available at: https://www.researchgate.net/publication/348603525_Healthy_China_2030_a_plan_towards_growth_development_and_innovation_in_health_sector (accessed 11.06.2025).Santiago A. Healthy China 2030: a plan towards growth, development and innovation in health sector. 2021. Available at: https://www.researchgate.net/publication/348603525_Healthy_China_2030_a_plan_towards_growth_development_and_innovation_in_health_sector (accessed 11.06.2025).Hu M., Hao Z., Yin Y. Promoting the integration of elderly healthcare and elderly nursing: evidence from the Chinese government. Int J Environ Res Public Health. 2022; 19 (24): 16379. https://doi.org/10.3390/ijerph192416379.Hu M., Hao Z., Yin Y. Promoting the integration of elderly healthcare and elderly nursing: evidence from the Chinese government. Int J Environ Res Public Health. 2022; 19 (24): 16379. https://doi.org/10.3390/ijerph192416379.Yang Y., Meng Y. Is China moving toward healthy aging? A tracking study based on 5 phases of CLHLS data. Int J Environ Res Public Health. 2020; 17 (12): 4343. https://doi.org/10.3390/ijerph17124343.Yang Y., Meng Y. Is China moving toward healthy aging? A tracking study based on 5 phases of CLHLS data. Int J Environ Res Public Health. 2020; 17 (12): 4343. https://doi.org/10.3390/ijerph17124343.Krings M.F., van Wijngaarden J.D., Yuan S., Huijsman R. China's elder care policies 1994–2020: a narrative document analysis. Int J Environ Res Public Health. 2022; 19 (10): 6141. https://doi.org/10.3390/ijerph19106141.Krings M.F., van Wijngaarden J.D., Yuan S., Huijsman R. China's elder care policies 1994–2020: a narrative document analysis. Int J Environ Res Public Health. 2022; 19 (10): 6141. https://doi.org/10.3390/ijerph19106141.Bhuiyan M.A., Galdes N., Cuschieri S., et al. A comparative systematic review of risk factors, prevalence, and challenges contributing to non-communicable diseases in South Asia, Africa, and Caribbeans. J Health Popul Nutr. 2024; 43: 140. https://doi.org/10.1186/s41043-024-00607-2.Bhuiyan M.A., Galdes N., Cuschieri S., et al. A comparative systematic review of risk factors, prevalence, and challenges contributing to non-communicable diseases in South Asia, Africa, and Caribbeans. J Health Popul Nutr. 2024; 43: 140. https://doi.org/10.1186/s41043-024-00607-2.Owusu M.F., Adu J., Dortey B.A., et al. Exploring health promotion efforts for non-communicable disease prevention and control in Ghana. PLoS Glob Public Health. 2023; 3 (9): e0002408. https://doi.org/10.1371/journal.pgph.0002408.Owusu M.F., Adu J., Dortey B.A., et al. Exploring health promotion efforts for non-communicable disease prevention and control in Ghana. PLoS Glob Public Health. 2023; 3 (9): e0002408. https://doi.org/10.1371/journal.pgph.0002408.Niohuru I. Healthcare and disease burden in Africa: the impact of socioeconomic factors on public health. Disease burden and mortality. Springer; 2023: 35–85. https://doi.org/10.1007/978-3-031-19719-2_3.Niohuru I. Healthcare and disease burden in Africa: the impact of socioeconomic factors on public health. Disease burden and mortality. Springer; 2023: 35–85. https://doi.org/10.1007/978-3-031-19719-2_3.Быкова А.В., Солодухин К.С. Проблемы финансового обеспечения систем здравоохранения и распределения инвестиций в общественное здоровье. Креативная экономика. 2022; 16 (2): 717–38. https://doi.org/10.18334/ce.16.2.114188.Bykova A.V., Solodukhin K.S. Problems of healthcare financial support and investment in public health. Creative Economy. 2022; 16 (2): 717–38 (in Russ.). https://doi.org/10.18334/ce.16.2.114188.Zeeb H., Loss J., Starke D., et al. Public health in Germany: structures, dynamics, and ways forward. Lancet Public Health. 2025; 10 (4): e333–42. https://doi.org/10.1016/S2468-2667(25)00033-7.Zeeb H., Loss J., Starke D., et al. Public health in Germany: structures, dynamics, and ways forward. Lancet Public Health. 2025; 10 (4): e333–42. https://doi.org/10.1016/S2468-2667(25)00033-7.Jakubowski S., Holko P., Nowak R., et al. Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries. Front Pharmacol. 2024; 15: 1498386. https://doi.org/10.3389/fphar.2024.1498386.Jakubowski S., Holko P., Nowak R., et al. Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries. Front Pharmacol. 2024; 15: 1498386. https://doi.org/10.3389/fphar.2024.1498386.Gerkens S., Merkur S. Belgium: health system review. Health Syst Transit. 2020; 22 (5): 1–237.Gerkens S., Merkur S. Belgium: health system review. Health Syst Transit. 2020; 22 (5): 1–237.Kruk M.E., Gage A.D., Arsenault C., et al. High-quality health systems in the Sustainable Development Goals era: time for a revolution. Lancet Glob Health. 2018; 6 (11): e1196–252. https://doi.org/10.1016/S2214-109X(18)30386-3.Kruk M.E., Gage A.D., Arsenault C., et al. High-quality health systems in the Sustainable Development Goals era: time for a revolution. Lancet Glob Health. 2018; 6 (11): e1196–252. https://doi.org/10.1016/S2214-109X(18)30386-3.Hanson K., Brikci N., Erlangga D., et al. The Lancet Global Health Commission on financing primary health care: putting people at the centre. Lancet Glob Health. 2022; 10 (5): e715–72. https://doi.org/10.1016/S2214-109X(22)00005-5.Hanson K., Brikci N., Erlangga D., et al. The Lancet Global Health Commission on financing primary health care: putting people at the centre. Lancet Glob Health. 2022; 10 (5): e715–72. https://doi.org/10.1016/S2214-109X(22)00005-5.Гречушкина Н.А. Экономика управления на уровне первичного звена здравоохранения в зарубежных странах: экспертный обзор. URL: https://niioz.ru/upload/iblock/ae4/ae4be27cb9c56eed576043ce86cae506.pdf (дата обращения 11.06.2025).Grechushkina N.A. Management economics at the primary health care level in foreign countries: expert review. Available at: https://niioz.ru/upload/iblock/ae4/ae4be27cb9c56eed576043ce86cae506.pdf (in Russ.) (accessed 11.06.2025).Docteur E., Landers R.M., Cole B., et al. Examining approaches to expand medicare eligibility: key design options and implications. Available at: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550074 (accessed 11.06.2025).Docteur E., Landers R.M., Cole B., et al. Examining approaches to expand medicare eligibility: key design options and implications. Available at: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550074 (accessed 11.06.2025).Crowley R., Daniel H., Cooney T.G., et al. Envisioning a better U.S. health care system for all: coverage and cost of care. Ann Intern Med. 2020; 172 (2 Suppl.): S7–32. https://doi.org/10.7326/M19-2415.Crowley R., Daniel H., Cooney T.G., et al. Envisioning a better U.S. health care system for all: coverage and cost of care. Ann Intern Med. 2020; 172 (2 Suppl.): S7–32. https://doi.org/10.7326/M19-2415.Sorum P.C., Stein C., Moore D.L. “Comprehensive Healthcare for America”: using the insights of behavioral economics to transform the U.S. Healthcare System. J Law Med Ethics. 2023; 51 (1): 153–71. https://doi.org/10.1017/jme.2023.52.Sorum P.C., Stein C., Moore D.L. “Comprehensive Healthcare for America”: using the insights of behavioral economics to transform the U.S. Healthcare System. J Law Med Ethics. 2023; 51 (1): 153–71. https://doi.org/10.1017/jme.2023.52.Martinez R.M., Osei-Anto H.A., McCormick M. (Eds) Addressing sickle cell disease: a strategic plan and blueprint for action. Washington (DC): National Academies Press (US), 2020. Available at: https://www.ncbi.nlm.nih.gov/books/NBK566454 (accessed 11.06.2025).Martinez R.M., Osei-Anto H.A., McCormick M. (Eds) Addressing sickle cell disease: a strategic plan and blueprint for action. Washington (DC): National Academies Press (US), 2020. Available at: https://www.ncbi.nlm.nih.gov/books/NBK566454 (accessed 11.06.2025).Singh Thakur J., Nangia R., Singh S. Progress and challenges in achieving noncommunicable diseases targets for the sustainable development goals. FASEB Bioadv. 2021; 3 (8): 563–8. https://doi.org/10.1096/fba.2020-00117.Singh Thakur J., Nangia R., Singh S. Progress and challenges in achieving noncommunicable diseases targets for the sustainable development goals. FASEB Bioadv. 2021; 3 (8): 563–8. https://doi.org/10.1096/fba.2020-00117.Japan Health System Review. Health Syst Transit. 2018; 8 (1): 1–248.Japan Health System Review. Health Syst Transit. 2018; 8 (1): 1–248.Ji S., Lee M., Choi M., Park S. The impact of the expanded health insurance coverage policy on healthcare spending: evidence from Korea. Int J Equity Health. 2024; 23 (1): 126. https://doi.org/10.1186/s12939-024-02206-3.Ji S., Lee M., Choi M., Park S. The impact of the expanded health insurance coverage policy on healthcare spending: evidence from Korea. Int J Equity Health. 2024; 23 (1): 126. https://doi.org/10.1186/s12939-024-02206-3.Bloom D.E., Chen S., Kuhn M., et al. The economic burden of chronic diseases: Estimates and projections for China, Japan, and South Korea. J Econ Ageing. 2020; 17: 100163. https://doi.org/10.1016/j.jeoa.2018.09.002.Bloom D.E., Chen S., Kuhn M., et al. The economic burden of chronic diseases: Estimates and projections for China, Japan, and South Korea. J Econ Ageing. 2020; 17: 100163. https://doi.org/10.1016/j.jeoa.2018.09.002.Durizzo K., Harttgen K., Tediosi F., et al. Toward mandatory health insurance in low-income countries? An analysis of claims data in Tanzania. Health Econ. 2022; 31 (10): 2187–207. https://doi.org/10.1002/hec.4568.Durizzo K., Harttgen K., Tediosi F., et al. Toward mandatory health insurance in low-income countries? An analysis of claims data in Tanzania. Health Econ. 2022; 31 (10): 2187–207. https://doi.org/10.1002/hec.4568.Yenet A., Nibret G., Tegegne B.A. Challenges to the availability and affordability of essential medicines in African countries: a scoping review. Clinicoecon Outcomes Res. 2023; 15: 443–58. https://doi.org/10.2147/CEOR.S413546.Yenet A., Nibret G., Tegegne B.A. Challenges to the availability and affordability of essential medicines in African countries: a scoping review. Clinicoecon Outcomes Res. 2023; 15: 443–58. https://doi.org/10.2147/CEOR.S413546.Karamagi H.C., Njuguna D., Kidane S.N., et al. Financing health system elements in Africa: a scoping review. PLoS One. 2023; 18 (9): e0291371. https://doi.org/10.1371/journal.pone.0291371.Karamagi H.C., Njuguna D., Kidane S.N., et al. Financing health system elements in Africa: a scoping review. PLoS One. 2023; 18 (9): e0291371. https://doi.org/10.1371/journal.pone.0291371.Тельнова Е.А. Организация лекарственного обеспечения в Российской Федерации. Бюллетень Национального научно-исследовательского института общественного здоровья имени Н.А. Семашко. 2021; 1: 100–11. https://doi.org/10.25742/NRIPH.2021.01.013.Telnova E.A. Organization of drug supply in the Russian Federation. Bulletin of Semashko National Research Institute of Public Health. 2021; 1: 100–11 (in Russ.). https://doi.org/10.25742/NRIPH.2021.01.013.Takawira B., Pooe D., Samuels A. Assessing disruptions in pharmaceutical supply chains: a qualitative study of resilience and risks in the South African context. J Econ Soc Develop. 2024; 11 (2): 43–62.Takawira B., Pooe D., Samuels A. Assessing disruptions in pharmaceutical supply chains: a qualitative study of resilience and risks in the South African context. J Econ Soc Develop. 2024; 11 (2): 43–62.Jailobaeva K., Falconer J., Loffreda G., et al. An analysis of policy and funding priorities of global actors regarding noncommunicable disease in low- and middle-income countries. Global Health. 2021; 17 (1): 68. https://doi.org/10.1186/s12992-021-00713-4.Jailobaeva K., Falconer J., Loffreda G., et al. An analysis of policy and funding priorities of global actors regarding noncommunicable disease in low- and middle-income countries. Global Health. 2021; 17 (1): 68. https://doi.org/10.1186/s12992-021-00713-4.Adebisi Y.A., Nwogu I.B., Alaran A.J., et al. Revisiting the issue of access to medicines in Africa: challenges and recommendations. Public Health Chall. 2022; 1 (2): e9. https://doi.org/10.1002/puh2.9.Adebisi Y.A., Nwogu I.B., Alaran A.J., et al. Revisiting the issue of access to medicines in Africa: challenges and recommendations. Public Health Chall. 2022; 1 (2): e9. https://doi.org/10.1002/puh2.9.Овод А.И. Финансирование системы лекарственного обеспечения Российской Федерации. Иннов: электронный научный журнал. 2017; 4. Ovod A.I. Financing of pharmaceutical supply systems of the Russian Federation. Innov: Electronic Scientific Journal. 2017; 4 (in Russ.).Овод А.И. Финансирование системы лекарственного обеспечения Российской Федерации. Иннов: электронный научный журнал. 2017; 4. Ovod A.I. Financing of pharmaceutical supply systems of the Russian Federation. Innov: Electronic Scientific Journal. 2017; 4 (in Russ.).Улумбекова Г.Э., Медик В.А. (ред.) Общественное здоровье и здравоохранение. Национальное руководство. Гл. 16. Лекарственное обеспечение населения в РФ. М.: ГЭОТАР-Медиа; 2022: 1144 с.Ulumbekova G.E., Medik V.A. (Eds) Public health and healthcare. National guide. Chapter 16. Drug supply of the population in the Russian Federation. Moscow: GEOTAR-Media; 2022: 1144 pp. (in Russ.).Соболева Е.А. Бюджетно-страховая модель финансирования здравоохранения в России. Финансы: теория и практика. 2021; 25 (3): 127–49. https://doi.org/10.26794/2587-5671-2021-25-3-127-149.Soboleva E.A. The budgetary and insurance model of healthcare funding in Russia. Finance: Theory and Practice. 2021; 25 (3): 127–49 (in Russ.). https://doi.org/10.26794/2587-5671-2021-25-3-127-149.Петров А.Г., Хорошилова О.В., Филимонов С.Н., Семенихин В.А. Методологические основы организации специализированной фармацевтической помощи больным с социально-значимыми заболеваниями. Медицина в Кузбассе. 2025; 24 (1): 77–82. https://doi.org/10.24412/2687-0053-2025-1-77-82.Petrov A.G., Khoroshilova O.V., Filimonov S.N., Semenikhin V.A. Methodological foundations of the organization specialized pharmaceutical care for patients with socially significant diseases. Medicine in Kuzbass. 2025; 24 (1): 77–82 (in Russ.). https://doi.org/10.24412/2687-0053-2025-1-77-82.Толузаков А.К. Современные тенденции и угрозы в обеспечении лекарственными препаратами населения России. KANT. 2021; 2: 106–10.Toluzakov A.K. Current trends and threats in the provision of medicines to the population of Russia. KANT. 2021; 2: 106–10 (in Russ.).Aghajanyan S., Karapetyan L., Petrosyan A., et al. The necessity of introduction the drug insurance system in Armenia. World Science. 2022; 5: 67–75. https://doi.org/10.31435/rsglobal_ws/30092022/7871.Aghajanyan S., Karapetyan L., Petrosyan A., et al. The necessity of introduction the drug insurance system in Armenia. World Science. 2022; 5: 67–75. https://doi.org/10.31435/rsglobal_ws/30092022/7871.Or Z., Gandré C., Seppänen A.V., et al. France: health system review. Health Syst Transit. 2023; 25 (3): 1–276.Or Z., Gandré C., Seppänen A.V., et al. France: health system review. Health Syst Transit. 2023; 25 (3): 1–276.Калашников К.Н. Проблема концептуализации категории «социально значимые заболевания» в стратегическом управлении. Экономические и социальные перемены: факты, тенденции, прогноз. 2024; 17 (2): 187–201. https://doi.org/10.15838/esc.2024.2.92.10.Kalashnikov K.N. Conceptualizing the notion of “socially significant diseases” in strategic planning. Economic and Social Changes: Facts, Trends, Forecast. 2024; 17 (2): 187–201. https://doi.org/10.15838/esc.2024.2.92.10.Шевченко С.Б., Пузин С.Н., Шургая М.А., Осадчук М.А. Социально значимые заболевания в нозологической структуре инвалидности граждан пожилого возраста в Российской Федерации. Сеченовский вестник. 2016; 3: 4–11.Shevchenko S.B., Puzin S.N., Shurgaya M.A., Osadchuk M.A. Socially significant diseases in the disability nosological structure in the elderly in the Russian Federation. Sechenov Medical Journal. 2016; 3: 4–11 (in Russ.).Marques L., Costa B., Pereira M., et al. Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics. 2024; 16 (3): 332. https://doi.org/10.3390/pharmaceutics16030332.Marques L., Costa B., Pereira M., et al. Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics. 2024; 16 (3): 332. https://doi.org/10.3390/pharmaceutics16030332.Vudathaneni V.K.P., Lanke R.B., Mudaliyar M.C., et al. The impact of telemedicine and remote patient monitoring on healthcare delivery: a comprehensive evaluation. Cureus. 2024; 16 (3): e55534. https://doi.org/10.7759/cureus.55534.Vudathaneni V.K.P., Lanke R.B., Mudaliyar M.C., et al. The impact of telemedicine and remote patient monitoring on healthcare delivery: a comprehensive evaluation. Cureus. 2024; 16 (3): e55534. https://doi.org/10.7759/cureus.55534.Тимербулатова Л.И. Приоритетные направления государственной политики в сфере здравоохранения. Молодой ученый. 2017; 40: 140–2.Timerbulatova L.I. Priority directions of state policy in the sphere of health care. Molodoy uchenyy / Young Scientist. 2017; 40: 140–2 (in Russ.).

The authors declare that there are no conflicts of interest present.